Shire puts Fabry drug plant in Genzyme's back yard; CryoPort brings green to frozen shipping;

> Irish drugmaker Shire says the European Medicines Agency has approved a new manufacturing site for Fabry disease treatment Replagal in Lexington, MA, a mere 10 miles from the Genzyme plant now under consent decree remediation, site of Fabrazyme production. Item

> Cold chain provider CryoPort says it's targeting the frozen shipping market with products that both benefit life sciences companies and represent "green" technology solutions. Article

> Fakes fighter and brand protection specialist Sproxil, known for pioneering efforts in cell-phone-based drug authentication in Nigeria, has received $1.8 million from Acumen to kick start the technology in India and East Africa. Item

> A seasoned crop of pharma execs have launched BioEndpoint Consulting, targeting small and mid-sized drugmakers navigating the intricacies of development and commercialization. Release

> Process analytical instrument maker Applied Instrument Technologies has opened its new corporate HQ and manufacturing facility in Upland, CA. Release

> Pfizer has teamed with the U.S. Department of Homeland Security and Eaton in a National Press Club panel discussion on the growing threat of counterfeit products. Announcement

> Novato, CA-based biotech BioMarin Pharmaceutical says it will pay $48.5 million to acquire a 10-acre manufacturing plant in Ireland from Pfizer. Story

> A high-end May & Baker drug plant now graces Ota in Ogun State, Nigeria; 10,769 square meters for capacity of 4 billion tablets, 30 million bottles of liquid preparation annually; man/material movement in non-crossing patterns for separate personnel and material flows; and WHO, FDA and other globally recognized regulatory compliance. Story

> A Scottish chemical factory on the verge of closing has been taken over by Bakhu Pharma for manufacturing anti-cholesterol and HIV drugs. Story

> The Serbian government, which will provide a $100 million loan, said last week that drugmaker Galenika can resume production, avoiding a national drug shortage. Article